Key Insights

Highlights

Success Rate

95% trial completion (above average)

Research Maturity

59 completed trials (87% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.4%

3 terminated out of 68 trials

Success Rate

95.2%

+8.7% vs benchmark

Late-Stage Pipeline

26%

18 trials in Phase 3/4

Results Transparency

17%

10 of 59 completed with results

Key Signals

10 with results95% success

Data Visualizations

Phase Distribution

60Total
Not Applicable (7)
P 1 (9)
P 2 (26)
P 3 (11)
P 4 (7)

Trial Status

Completed59
Recruiting3
Terminated3
Unknown2
Not Yet Recruiting1

Trial Success Rate

95.2%

Benchmark: 86.5%

Based on 59 completed trials

Clinical Trials (68)

Showing 20 of 20 trials
NCT04502966Phase 2CompletedPrimary

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT06922448Phase 2CompletedPrimary

Study of BLU-808 in Allergic Rhinoconjunctivitis

NCT07060885Phase 3RecruitingPrimary

A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

NCT05668390Phase 3CompletedPrimary

Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma

NCT06448585Phase 4Completed

Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.

NCT07042828Phase 1CompletedPrimary

To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions

NCT06778213Phase 4RecruitingPrimary

Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Assessment in an Allergen Exposure chamber-a Randomized Placebo-controlled Double-blind Study

NCT05192720Not ApplicableCompleted

Andosan in Allergic and Asthma Patients

NCT01433510Phase 4CompletedPrimary

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

NCT02159404RecruitingPrimary

Nasal Mucus Proteome and Immunotherapy

NCT04874714Phase 3TerminatedPrimary

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

NCT05455749Not ApplicableCompleted

Effect of holoBLG on Cat Allergic Patients

NCT04912076Phase 1Completed

S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen

NCT05641272Phase 2Not Yet Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

NCT04541004Phase 3Completed

Adolescent Mite Allergy Safety Evaluation

NCT05400811Phase 3Unknown

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

NCT04176185Phase 3TerminatedPrimary

A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber

NCT04898686Not ApplicableCompletedPrimary

Probiotic Chewables in Allergic Rhinoconjunctivitis Patients

NCT03682965Phase 2Completed

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03850626CompletedPrimary

Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients

Scroll to load more

Research Network

Activity Timeline